| Literature DB >> 34519269 |
Maren Heimhalt1, Alex Berndt1, Jane Wagstaff1, Madhanagopal Anandapadamanaban1, Olga Perisic1, Sarah Maslen1, Stephen McLaughlin1, Conny Wing-Heng Yu1, Glenn R Masson1, Andreas Boland2, Xiaodan Ni1, Keitaro Yamashita1, Garib N Murshudov1, Mark Skehel1, Stefan M Freund1, Roger L Williams1.
Abstract
The mTORC1 kinase complex regulates cell growth, proliferation, and survival. Because mis-regulation of DEPTOR, an endogenous mTORC1 inhibitor, is associated with some cancers, we reconstituted mTORC1 with DEPTOR to understand its function. We find that DEPTOR is a unique partial mTORC1 inhibitor that may have evolved to preserve feedback inhibition of PI3K. Counterintuitively, mTORC1 activated by RHEB or oncogenic mutation is much more potently inhibited by DEPTOR. Although DEPTOR partially inhibits mTORC1, mTORC1 prevents this inhibition by phosphorylating DEPTOR, a mutual antagonism that requires no exogenous factors. Structural analyses of the mTORC1/DEPTOR complex showed DEPTOR's PDZ domain interacting with the mTOR FAT region, and the unstructured linker preceding the PDZ binding to the mTOR FRB domain. The linker and PDZ form the minimal inhibitory unit, but the N-terminal tandem DEP domains also significantly contribute to inhibition.Entities:
Keywords: DEPTOR; biochemistry; cancer; chemical biology; cryo-EM; human; mTOR; molecular biophysics; partial inhibition; signal transduction; structural biology
Mesh:
Substances:
Year: 2021 PMID: 34519269 PMCID: PMC8439657 DOI: 10.7554/eLife.68799
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140